Answers are grounded in this paper and cite their sources.
In recent years, bispecific antibodies (bsAb) have emerged as promising tools for a target-specific redirection of T cells in order to eliminate malignant cells. However, CD3-engaging constructs might also activate T regulatory cells (Tregs) present in the tumor microenvironment. Whether this has detrimental or beneficial effects for tumor therapy is still controversially discussed.
No takes yet. Share an insight, caveat, or question.
Koristka et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: